Inherited Optic Neuropathy
Gensight Biologics focuses on Leber Hereditary Optic Neuropathy linked to mutations in the mitochondrial ND4 gene, with research centered on preserving and improving visual acuity in affected patients.
- ND4-related LHON
- Visual function
- Retinal mitochondrial activity
The sponsor’s work in this area is directed toward gene-based ophthalmic treatment for a rare hereditary disorder that causes rapid and severe vision loss.
Retinal Dystrophy
The company also studies retinitis pigmentosa, with interest in non-syndromic forms of the disease affecting retinal structure and progressive vision decline.
- Non-syndromic retinitis pigmentosa
- Inherited retinal disease
- Photoreceptor dysfunction
Research in this field reflects a therapeutic focus on retinal gene therapy and vision-related outcomes in degenerative eye disease.
Ophthalmic Gene Therapy
Gensight Biologics is active in gene therapy for ocular disorders, with clinical interest in restoring or supporting retinal function through targeted genetic approaches.
- Intravitreal administration
- Ocular genetic intervention
- Retinal treatment development
This area places the sponsor within the field of advanced ophthalmology, particularly for inherited conditions with limited existing treatment options.
Vision Preservation
The sponsor’s trials are oriented toward maintaining central vision and slowing functional decline in patients with rare retinal and optic nerve disorders.
- Best-corrected visual acuity
- Retinal function
- Hereditary vision loss
Its clinical research activity is concentrated in rare eye diseases that involve inherited degeneration of the optic nerve or retina.
